[{"figure_path": "HeoRsnaD44/tables/tables_6_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table compares several methods for ligand-based drug design, focusing on their ability to generate molecules with similar 3D shapes to a reference ligand.  The methods are categorized into non-diffusion-based and diffusion-based approaches. Metrics include shape similarity, graph similarity, the ratio between them, and diversity.  The table highlights the superior performance of UniGuide compared to the specialized methods in generating ligands with similar shapes but diverse structures.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_7_1.jpg", "caption": "Table 2: Structure-Based Drug Design. Quantitative comparison of generated ligands for target pockets from the CrossDocked and Binding MOAD test sets. Results taken from the respective works are indicated with (*). We highlight the best conditioning approach for the DiffSBDD backbone in bold and underline the best approach over all methods.", "description": "This table quantitatively compares the performance of UniGuide against several state-of-the-art baselines on two structure-based drug design datasets (CrossDocked and Binding MOAD).  The metrics used are Vina Score (lower is better, indicating higher binding affinity), Vina Min (lower is better, indicating better binding in the best docking pose), Vina Dock (lower is better), QED (Quantitative Estimate of Drug-likeness, higher is better), and SA (Synthetic Accessibility, higher is better).  The table highlights UniGuide's competitive performance, often outperforming specialized methods.", "section": "5.2 Structure-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_8_1.jpg", "caption": "Table 3: Linker Design. Results taken from Igashov et al. [13] are indicated with (*). We underline the best method overall.", "description": "This table compares the performance of different methods for linker design, a subtask of fragment-based drug design.  It evaluates several methods including DeLinker, 3DLinker, DiffLinker and UniGuide across various metrics: QED (quantitative estimate of drug-likeness), SA (synthetic accessibility), Number of Rings, Valid (percentage of valid molecules), Unique (percentage of unique molecules), 2D Filters (number of 2D filters), and Recovery (percentage of recovered ligands). The results show that UniGuide (using EDM), while not specifically designed for this task, achieves comparable or better results than specialized methods like DiffLinker, particularly in terms of generating unique and valid linkers. The results highlight the versatility of the UniGuide framework.", "section": "5.3 Fragment-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_17_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table compares various methods for ligand-based drug design, focusing on shape similarity and diversity. It presents quantitative results from different approaches, including non-diffusion-based methods (VS, SQUID, ShapeMol) and diffusion-based methods (ShapeMol+g, UniGuide with ShapeMol and EDM).  The metrics used for evaluation are shape similarity, maximum shape similarity, graph similarity, maximum graph similarity, ratio of shape to graph similarity, diversity, and the number of valid molecules generated. The results demonstrate that UniGuide, even when using simpler unconditional models, can achieve performance comparable to or better than specialized models.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_18_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table presents a comparison of different methods for ligand-based drug design, focusing on the ability to generate molecules with similar 3D shapes to a reference ligand.  The table includes several non-diffusion and diffusion-based methods, evaluating metrics such as shape similarity, graph similarity, ratio (shape similarity to graph similarity), diversity, and drug-likeness (QED).  The results highlight UniGuide's performance against specialized models for LBDD.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_20_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table presents the quantitative comparison of different methods for ligand-based drug design.  The results from Chen et al. [14] are marked with an asterisk (*). The table highlights the best conditioning approach for the ShapeMol backbone (a specific method) in bold font and underlines the overall best performing method across all compared approaches.  Metrics used for comparison include shape similarity, maximum shape similarity, graph similarity, maximum graph similarity, ratio of shape and graph similarity, diversity of generated molecules, and quantitative estimation of drug-likeness.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_20_2.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table presents the quantitative comparison of different methods for ligand-based drug design, specifically focusing on the ability to generate molecules with similar 3D shapes to a reference ligand while maintaining diversity and other desirable properties.  The results are organized by model type (non-diffusion-based vs. diffusion-based), and key metrics include shape similarity, maximum shape similarity, graph similarity, maximum graph similarity, ratio of shape similarity to graph similarity, diversity, and QED. The table shows that UniGuide (with ShapeMol and EDM as base models) performs either comparably to or better than task-specific baselines like ShapeMol and SQUID.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_21_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table compares different methods for ligand-based drug design, focusing on the ability to generate molecules with similar 3D shapes to a reference molecule while maintaining diversity.  It shows the performance of various methods using several metrics, including shape similarity, graph similarity (to measure dissimilarity in molecular structure), diversity, and drug-likeness properties (QED, Ratio, and Lipinski).  The results indicate that UniGuide with EDM achieves competitive or superior results to other specialized methods.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_22_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table compares different methods for ligand-based drug design, focusing on the ability to generate molecules with similar 3D shapes to a reference molecule. It presents results from various methods, including those based on diffusion models and other techniques.  The metrics used to assess performance include shape similarity, maximum shape similarity, graph similarity, maximum graph similarity, the ratio of shape to graph similarity, diversity, and QED. The table highlights the best performance achieved using each method and across all methods.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_22_2.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table compares various methods for ligand-based drug design, focusing on shape similarity and diversity.  It shows the performance of different models, including several diffusion-based approaches and a non-diffusion-based virtual screening method, across multiple metrics.  The table highlights UniGuide's competitive performance and superior diversity.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_23_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table presents a comparison of various methods for ligand-based drug design, focusing on the ability to generate molecules with similar 3D shapes to a reference ligand.  The metrics used to evaluate performance include shape similarity, maximum shape similarity, graph similarity, maximum graph similarity, the ratio of shape similarity to graph similarity (a key metric reflecting the tradeoff between similar shape and dissimilar structure), diversity, and quantitative estimated drug-likeness (QED).  Several baselines are compared against UniGuide, showcasing UniGuide's performance with different unconditional models.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_23_2.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table compares the performance of UniGuide against other methods for ligand-based drug design.  Several metrics are used to evaluate the generated molecules, including shape similarity (Sims, maxSims), graph similarity (Simg, maxSimg), diversity, and the ratio of shape to graph similarity. The results demonstrate that UniGuide, even when using an unconditional model, can outperform specialized, conditional models.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_24_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table presents a comparison of different methods for ligand-based drug design.  The methods are categorized into non-diffusion-based and diffusion-based approaches.  For each method, the table shows the shape similarity (Sims and maxSims), graph similarity (Simg and maxSimg), the ratio of shape similarity to graph similarity, and the diversity of generated molecules. The best performing method in each category is highlighted in bold, and the overall best-performing method is underlined.  Results from a prior study by Chen et al. are marked with an asterisk.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_24_2.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table presents a comparison of different methods for ligand-based drug design, focusing on the ability to generate molecules with similar 3D shapes to a reference ligand while maintaining diversity and other desirable properties.  The results are evaluated using metrics such as shape similarity, graph similarity, ratio of shape to graph similarity, diversity, and drug-likeness.", "section": "5.1 Ligand-based drug design"}, {"figure_path": "HeoRsnaD44/tables/tables_25_1.jpg", "caption": "Table 1: Ligand-Based Drug Design. Results taken from Chen et al. [14] are indicated with (*). We highlight the best conditioning approach for the ShapeMol backbone in bold and underline the best approach across all methods.", "description": "This table presents a comparison of different methods for ligand-based drug design, focusing on the ability to generate molecules with similar 3D shapes to a reference ligand.  The table includes both non-diffusion and diffusion-based methods, and various metrics are reported to evaluate the performance, including shape similarity, graph similarity, ratio of shape to graph similarity (to capture the tradeoff between generating similar shapes while maintaining diversity), diversity of generated molecules, and the overall quality of the generated molecules (QED).  The results highlight UniGuide's competitive or superior performance compared to other specialized models.", "section": "5.1 Ligand-based drug design"}]